For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
Olema Pharmaceuticals Inc (NASDAQ: OLMA) closed the day trading at $28.12 up 7.86% from the previous closing price of $26.07. In other words, the price has increased by $7.86 from its previous closing price. On the day, 4.12 million shares were traded. OLMA stock price reached its highest trading level at $29.51 during the session, while it also had its lowest trading level at $25.8.
Ratios:
For a better understanding of OLMA, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.03 and its Current Ratio is at 8.03. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In the most recent recommendation for this company, Guggenheim on October 08, 2025, initiated with a Buy rating and assigned the stock a target price of $20.
On August 12, 2025, Citigroup reiterated its Buy rating and also lowered its target price recommendation from $20 to $21. On April 02, 2024, Goldman started tracking the stock assigning a Buy rating and target price of $24.Goldman initiated its Buy rating on April 02, 2024, with a $24 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 18 ’25 when Harmon Cyrus sold 10,000 shares for $8.33 per share. The transaction valued at 83,300 led to the insider holds 744,140 shares of the business.
Harmon Cyrus sold 10,000 shares of OLMA for $80,400 on Sep 16 ’25. The Director now owns 754,140 shares after completing the transaction at $8.04 per share. On Sep 18 ’25, another insider, Harmon Cyrus, who serves as the Director of the company, sold 3,086 shares for $8.32 each. As a result, the insider received 25,676 and left with 117,028 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OLMA now has a Market Capitalization of 2254096896 and an Enterprise Value of 1606235008.
Stock Price History:
The Beta on a monthly basis for OLMA is 1.70, which has changed by 1.7786562 over the last 52 weeks, in comparison to a change of 0.12934029 over the same period for the S&P500. Over the past 52 weeks, OLMA has reached a high of $27.17, while it has fallen to a 52-week low of $2.86. The 50-Day Moving Average of the stock is 152.91%, while the 200-Day Moving Average is calculated to be 337.70%.
Shares Statistics:
Over the past 3-months, OLMA traded about 3.19M shares per day on average, while over the past 10 days, OLMA traded about 13976450 shares per day. A total of 68.65M shares are outstanding, with a floating share count of 63.38M. Insiders hold about 19.42% of the company’s shares, while institutions hold 86.06% stake in the company. Shares short for OLMA as of 1763078400 were 9364250 with a Short Ratio of 2.93, compared to 1760486400 on 7545885. Therefore, it implies a Short% of Shares Outstanding of 9364250 and a Short% of Float of 15.0.
Earnings Estimates
The market rating for Olema Pharmaceuticals Inc (OLMA) is a result of the insights provided by 7.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.56, with high estimates of -$0.53 and low estimates of -$0.61.
Analysts are recommending an EPS of between -$1.86 and -$2.37 for the fiscal current year, implying an average EPS of -$1.96. EPS for the following year is -$2.44, with 6.0 analysts recommending between -$1.86 and -$2.74.
